BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

2 years ago

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the…

Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem

2 years ago

DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

2 years ago

Four healthy subjects dosed with RECCE® 327 at 3,000mg over 20 minutesData received from this cohort will support preparations for…

Cytek® Biosciences Names William McCombe Chief Financial Officer

2 years ago

Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March…

HealthLynked Corp Announces Chris Hall as New Chief Technology Officer

2 years ago

NAPLES, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK), a leader in healthcare technology innovation,…

Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China

2 years ago

A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024…

Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain

2 years ago

EAACI Congress 2024 EAACI Congress 2024 https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy…

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

2 years ago

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI…

Repligen Appoints Maggie A. Pax to Board of Directors

2 years ago

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors…

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

2 years ago

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…